



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula:



wherein

ring A represents a benzene ring optionally having substituents;

B represents a C₁₋₆ alkylene optionally having substituents; Y and Ya are the same or different and each represents a bond or a spacer having a main chain of 1 to 6 atoms;

R¹ and R² are the same or different and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents;

R³ represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents;

R⁴ and R⁵ are the same or different and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R⁴ and R⁵, together with the adjacent carbon atom, form a ring optionally having substituents;

R⁶ represents an indolyl group optionally having substituents; and

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents; and

Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

2. (Canceled)

3. (Original) The compound according to claim 1, wherein R³ is a hydrogen atom or a C₁₋₆ alkyl optionally having substituents.

4. (Original) The compound according to claim 1, wherein one of R⁴ and R⁵ is a hydrogen atom, and the other is a C₁₋₆ alkyl optionally having substituents.

5-6. (Canceled)

7. (Previously Presented) The compound according to claim 1, wherein Z is piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd represents a bond or a spacer having a main chain of 1 to 6 atoms, and Ara represents a monocyclic group optionally having substituents.

8. (Original) The compound according to claim 1, wherein Ya is a bond, and Za is a hydrogen atom.

9. (Original) The compound according to claim 1, wherein B is a C₁₋₆ alkylene.

10. (Canceled)

11. (Original) The compound according to claim 1, wherein R¹ and R² are C₁₋₆ alkyl.

12. (Original) The compound according to claim 1, wherein Y is -CO-.

13. (Original) The compound according to claim 1, which is

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-((methylamino)carbonyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((2-((dimethylamino)carbonyl)-5-((dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluoro-2-methylphenyl)-3-oxo-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperazinecarboxamide; or

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-phenyl-1-piperidinecarboxamide.

14. (Previously Presented) A pharmaceutical preparation comprising the compound according to claim 1 or a salt thereof.

15. (Original) The pharmaceutical preparation according to claim 14, which is a somatostatin receptor binding inhibitor.

16. (Original) The pharmaceutical preparation according to claim 15, which is a somatostatin subtype 2 receptor binding inhibitor.

17. (Original) The pharmaceutical preparation according to claim 14, which is a somatostatin receptor agonist.

18. (Original) The pharmaceutical preparation according to claim 17, which is a somatostatin subtype 2 receptor agonist.

19. (Original) The pharmaceutical preparation according to claim 14, which is a prophylactic or therapeutic agent for diabetes or diabetic complications.

20. (Original) The pharmaceutical preparation according to claim 14, which is a prophylactic or therapeutic agent for obesity.

21. (Canceled)

22. (Currently Amended) A method for inhibiting somatostatin receptor binding in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.


23. (Canceled)

24. (Previously Presented) A method for preventing or treating diabetes or diabetic complications in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

25. (Canceled)

26. (Previously Presented) A method for preventing or treating obesity in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

27. (Currently Amended) A method for producing a compound of claim 1 or a salt thereof, which comprises reacting a compound of the formula:





wherein

Y represents a bond or a spacer having a main chain of 1 to 6 atoms;

R⁴ and R⁵ are the same or different, and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R⁴ and R⁵, together with the adjacent carbon atom, form a ring optionally having substituents;

R⁶ represents an indolyl group optionally having substituents;

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents or a salt thereof, with a compound of the formula:





wherein

ring A represents a benzene ring optionally having substituents;

B represents a C₁₋₆ alkylene optionally having substituents;

R¹ and R² are the same or different, and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents;

R³ represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents; or a salt thereof to give a compound of the formula:



wherein

each symbol is as defined above; or a salt thereof, and optionally reacting the compound or a salt thereof with a compound of the formula: L⁴-Ya-Za wherein L⁴ represents a leaving group; Ya represents a bond or a spacer having a main chain of 1

to 6 atoms; Z_a represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

28. (Canceled)